Tenaya Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.3MTTM through 30 Jun 2026
Net Income -$90.6MTTM through 30 Jun 2026
Free Cash Flow -$52.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| Operating Margin | -6,991.1% |
| Net Margin | -6,786.3% |
Returns
-73.5%ROE
-61.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.84x
Net Debt-$100.5Mnet cash position
Cash & Equivalents$78.1M
Quality Metrics
Altman Z-Score-8.61
Piotroski F-Score1 / 9
FCF Margin-3,939.2%
Rule of 40-3,739.6
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$0.51TTMFY2025: $-0.59
Dividend
No dividend
Capital Allocation
R&D Spend$61.6M
Capex Intensity19.7%
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.